We are monitoring the impact of COVID-19 on Europe Therapeutic Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 57
Share on
Share on

Europe Therapeutic Vaccines Market Research Report – Segmented By Disease Type (Autoimmune Disease, Cancer, Neurological Disease, Infectious Disease) and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 57
Pages: 141

Europe Therapeutic Vaccines Market Size (2021 to 2026)

The size of the European Therapeutic Vaccines Market was estimated at 926.60 million USD in 2021. It is further expected to grow and be worth 3637.96 million USD by 2026, growing at a CAGR of 31.46% between 2021 and 2026.

Some of the factors propelling the European therapeutic vaccines market ahead include increased government funding for vaccine development, increased investments by leading market players, rising illness prevalence, technical advancements, and NGOs' activities.

Therapeutic vaccinations have grown in popularity as the prevalence of illnesses like cancer and HIV has increased. Technological advancements in HIV detection and expanded clinical trials for HIV and cancer vaccinations are two crucial factors accelerating the European therapeutic vaccines market. Furthermore, greater public awareness of critical illnesses and increased R&D spending in therapeutic vaccines boost the market for therapeutic vaccines in this region.

The massive growth has considerably influenced the European market for therapeutic vaccines in the prevalence of chronic illnesses such as cancer, HIV, and cardiovascular disorders. The world's attention has switched to therapeutic vaccinations as the need for effective therapy has risen alarmingly. Several pharmaceutical companies have developed novel vaccines for breast cancer, lung cancer, and Alzheimer's disease. Even though these developments are still in the works and have yet to be marketed, they indicate a new market potential for therapeutic vaccines throughout the world. Furthermore, malignancies caused by the human papillomavirus are anticipated to create a growing potential for the therapeutic vaccines market in Europe. 

Massive capital expenditures, strict regulatory restrictions, and expensive treatment costs are only a few factors that diminish the market's growth. Higher vaccination prices and a lack of therapeutic medication availability are limiting the European therapeutic vaccines market. Furthermore, tight regulatory criteria for therapeutic vaccine approval impeded the global therapeutic vaccines market. Ineffective research and development policies, as well as reimbursement regulations, are limiting the market. On the other hand, vaccination can cure a wide spectrum of chronic conditions, and these limitations will fade with time.

Clinical studies must be completed before a vaccine may be offered commercially. The majority of immunizations are rejected at every stage of the clinical study. By the time the finished product is licensed for commercial use, a significant amount of money has been spent on vaccine development R&D. These are some of the key challenges the market is currently facing.

This research report on the European therapeutic vaccines market has been segmented and sub-segmented into the following categories:

By Disease Type: 

  • Autoimmune Disease
  • Cancer
  • Neurological Disease
  • Infectious Disease

By Country: 

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Geographically, Europe is in a close race with North America in terms of market share in the global therapeutic vaccines market. A rise in autoimmune disease-related fatalities among women and children is to satisfy commercial demand. In addition, the market demand in this area is increasing as healthcare centers with novel procedures for chronic and deadly diseases grow.

The rise in the incidence of numerous chronic illnesses, including cancer, HIV, and cardiovascular diseases, has substantially influenced Europe's therapeutic vaccination industry. Because of the worrisome rise in demand for effective therapy, several pharmaceutical firms have begun developing innovative vaccinations for illnesses such as breast cancer, lung cancer, and Alzheimer's disease. The world's attention has shifted to therapeutic vaccines.  Therefore, despite the fact that these technologies are still in development and have yet to be commercialized, they point to a bright future for Europe's therapeutic vaccine market. 

KEY MARKET PLAYERS:

Companies playing a pivotal role in the European therapeutic vaccines market covered in this report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                               

                2.2 Analysis Design                                                         

                2.3 Research Phases                                                      

                                2.3.1 Secondary Research                                           

                                2.3.2 Primary Research                                 

                                2.3.3 Econometric Modelling                                      

                                2.3.4 Expert Validation                                  

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

  1. Market Segmentation

                5.1 By Disease Type                                                       

                                5.1.1 Autoimmune Disease Vaccines                                      

                                5.1.2 Cancer Vaccines                                    

                                                5.1.2.1 Multikine                             

                                                5.1.2.2 PR1 Peptide                        

                                                5.1.2.3 TroVax                  

                                                5.1.2.4 CYT004-MelQbG10                           

                                5.1.3 Neurological Disease Vaccines                                        

                                                5.1.3.1 ACC- 001                               

                                                5.1.3.2 CAD 106                

                                                5.1.3.3 Parkinson's Disease Vaccine                        

                                                5.1.3.4 Alzheimer's Disease                        

                                5.1.4 Infectious Disease Vaccines                                             

                                                5.1.4.1 Hepatitis C                           

                                                5.1.4.2 HIV/AIDS                              

                                                5.1.4.3 Other Infectious Disease                               

  1. Geographical Analysis

                6.1 Introduction                                                               

                6.2 U.K                                                 

                6.3 Spain                                                             

                6.4 Germany                                                     

                6.5 Italy                                                               

                6.6 France                                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

  1. Market Leaders' Analysis

                8.1 GlaxoSMithKline plc.                                                              

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                             

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Merck and Company                                                              

                8.3 Bavarian Nordic                                                        

                8.4 CSL Limited                                                 

                8.5 Emergent Biosolutions Inc.                                                  

                8.6 Novartis AG                                                

                8.7 Johnson and Johnson                                                            

                8.8 MedImmune LLC                                                     

                8.9 Pfizer Inc.                                                    

                8.10 Sanofi Pasteur                                                        

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

     Appendix                                                                           

  1. List of Tables
  2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  2. Europe Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  3. Europe Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  8. Europe Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  13. Europe ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  16. Europe Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  18. Europe Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  19. Europe HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  21. U.K. Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  22. Germany Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  23. France Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  24. Italy Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  25. Spain Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  26. U.K. Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  27. Germany Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  28. France Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  29. Italy Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  30. Spain Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  31. U.K. Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  32. Germany Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  33. France Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  34. Italy Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  35. Spain Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  36. U.K. Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  37. Germany Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  38. France Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  39. Italy Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  40. Spain Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample